Through the in-house R&D, Transcell Oncologics has built a pipeline of compelling group of druggable molecules for solid tumors. The Company is promptly progressing its discovery process tailored on patient derived primary screens for defined tumor types. By identifying and hunting from the intelligent toolbox, the selective killers of tumor resident progenitor cells causing both metastasis and cancer relapse, we have proffered 11 first-in-class candidates into the pipeline for Head & Neck, Colon cancers.